领晟医疗与西班牙公司Spherium Biomed于2019年4月23日达成合作协议，引进Spherium旗下治疗放化疗引起的口腔粘膜炎（SOM）产品—Mucomel®。 Mucomel®是一款口服口腔黏合剂，通过Ⅱ期POC验证，Mucomel可显著缓解放化疗引起的SOM，并降低发生率。
Link Health in-licensed Mucomel®
Guangzhou, China; 23 April 2019 - Link Health Pharma Co., Ltd. (“Link Health”) announced today that it has obitained exclusive regional rights for developing and commercialising Mucomel®.
Link Health has entered into a license and co-development agreement with Spanish company Spherium Biomed S.L. (“Spherium”) to develop and commercialise Mucomel® in Greater China and South Korea. Spherium is eligble to receive an upfront payment, milestones and low double digit royalties.
Mucomel® is a mucoadhesive oral gel under clinical development to prevent and treat oral mucositis in patients receiving radiation therapy. The incidence of oral mucositis is near 100% in head and neck cancer patients receiving radiation therapy, of which 85% are severe.
“Head and neck cancer has a high prelevence in Southern China, where Link Health’s headquarter is located.Mucomel® has shown great promise in being a breakthrough therapy to treat oral mucosits in both pre-clinical and clinical studies.” said Yan Song, CEO of Link Health. “We are pleased to partner with Spherium and excited to develop Mucomel® further in China. The clinical studies have been planned to start later this year.”
About Mucomel®
Mucomel® is a topical melatonin gel developed by Spherium, a majority owned company of Ferrer (www.ferrer.com). It is an oral mucoadhesive product with an excellent safety profile. The completed Phase lla clinical study has shown that Mucomel® significantly reduces the severity of cancer chemoradiotherapy-induced oral mucositis.
About Spherium Biomed
Spherium is a company that develops biomedical innovations from academic sources to accelerate their transition along the value chain and to the market. Mucomel® is based on a patented proprietary high-load gel formulation of melatonin licensed by Spherium from the University of Granada (Spain).
About Link Health
Link Health is a biopharmaceutical company developing innovative medicine for unmet medical needs. It has a drug development pipeline of 4 clinical stage assets and 1 under NDA reviewing in China. Headquartered in China, Link Health has an European office in the Netherlands to further strengthen the collaborations with global biopharmaceutical companies and research institutes.